Nerlynx Coupons & Savings Card – Discount Prices from $19342.02

Nerlynx is used as an extended adjuvant treatment for adult patients with early-stage HER2-positive breast cancer, following adjuvant trastuzumab-based therapy. It helps to reduce the risk of cancer recurrence.

Neratinib is not classified as a traditional chemotherapy drug. It is a type of targeted therapy known as a tyrosine kinase inhibitor, specifically used to treat certain types of breast cancer by targeting specific proteins involved in cancer cell growth.

Diarrhea associated with Nerlynx typically begins within the first few days to weeks of starting treatment. It is important for patients to follow their healthcare provider's instructions on managing this side effect, which may include taking antidiarrheal medications as a preventive measure.

Neratinib has shown a success rate in extending disease-free survival in patients with early-stage HER2-positive breast cancer. In clinical trials, it demonstrated a significant reduction in the risk of recurrence or death when used as an extended adjuvant therapy following trastuzumab-based treatment. The exact success rate can vary based on individual patient factors and specific study results, but it has been shown to improve outcomes in this patient population.

Neratinib causes diarrhea primarily because it affects the gastrointestinal tract. As a tyrosine kinase inhibitor, neratinib targets specific proteins involved in cell growth and division, including those in the lining of the intestines. This can disrupt normal cellular processes and lead to increased fluid secretion and motility in the intestines, resulting in diarrhea. This side effect is common with neratinib and is often managed with prophylactic antidiarrheal medications.